Nifty
:
22147.00
Sensex
:
73088.33
151.15 (0.69%)
599.34 (0.83%)
Nifty
Sensex
:
:
22147.00
73088.33
151.15 (0.69%)
599.34 (0.83%)

Alkem Laboratories Ltd.

Pharmaceuticals & Drugs - Domestic

Rating :
61/99

BSE: 539523 | NSE: ALKEM

NSE BSE
4616.35
19-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  4625.00
  •  4644.95
  •  4567.05
  •  4650.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  94277
  •  4340.76
  •  5520.00
  •  3186.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 55,102.73
  • 35.03
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 53,043.27
  • 1.08%
  • 5.27

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 56.74%
  • 0.10%
  • 18.31%
  • FII
  • DII
  • Others
  • 9.11%
  • 14.67%
  • 1.07%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.01
  • 9.53
  • 9.37

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.66
  • 7.62
  • -3.69

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.50
  • 5.29
  • -14.69

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.31
  • 27.29
  • 29.58

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.77
  • 4.72
  • 4.84

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.77
  • 19.65
  • 20.50

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
3,323.87
3,040.91
9.31%
3,440.17
3,079.37
11.72%
2,967.72
2,576.38
15.19%
2,902.60
2,483.86
16.86%
Expenses
2,616.28
2,441.86
7.14%
2,693.44
2,625.46
2.59%
2,578.53
2,373.14
8.65%
2,549.35
2,146.63
18.76%
EBITDA
707.59
599.05
18.12%
746.73
453.91
64.51%
389.19
203.24
91.49%
353.25
337.23
4.75%
EBIDTM
21.29%
19.70%
21.71%
-4.88%
13.11%
7.89%
12.17%
13.58%
Other Income
93.64
45.33
106.57%
63.19
50.67
24.71%
65.84
51.41
28.07%
68.67
20.52
234.65%
Interest
25.46
27.05
-5.88%
30.32
24.85
22.01%
29.77
26.50
12.34%
28.96
16.97
70.65%
Depreciation
69.56
78.44
-11.32%
73.90
77.40
-4.52%
72.41
76.26
-5.05%
78.32
83.14
-5.80%
PBT
654.90
538.89
21.53%
648.04
402.33
61.07%
352.85
151.89
132.31%
211.66
242.68
-12.78%
Tax
50.62
78.93
-35.87%
33.15
54.61
-39.30%
65.04
20.44
218.20%
143.98
134.47
7.07%
PAT
604.28
459.96
31.38%
614.89
347.72
76.83%
287.81
131.45
118.95%
67.68
108.21
-37.45%
PATM
18.18%
15.13%
17.87%
-10.84%
9.70%
5.10%
2.33%
4.36%
EPS
49.77
38.04
30.84%
51.90
-0.96
-
23.98
10.68
124.53%
5.94
9.00
-34.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
12,634.36
11,599.26
10,634.19
8,865.01
8,344.36
7,357.19
6,391.84
5,687.53
4,924.84
3,743.35
3,126.00
Net Sales Growth
13.00%
9.08%
19.96%
6.24%
13.42%
15.10%
12.38%
15.49%
31.56%
19.75%
 
Cost Of Goods Sold
5,085.70
4,381.43
3,565.78
3,124.81
2,959.14
2,586.30
1,986.45
1,807.71
1,630.87
1,453.41
1,168.05
Gross Profit
7,548.66
7,217.83
7,068.41
5,740.20
5,385.22
4,770.89
4,405.39
3,879.82
3,293.97
2,289.94
1,957.95
GP Margin
59.75%
62.23%
66.47%
64.75%
64.54%
64.85%
68.92%
68.22%
66.88%
61.17%
62.63%
Total Expenditure
10,437.60
9,989.81
8,581.27
6,922.62
6,870.97
6,242.42
5,382.92
4,688.58
4,071.59
3,321.52
2,716.05
Power & Fuel Cost
-
163.94
162.96
129.95
130.14
121.48
112.64
86.34
66.33
53.31
60.33
% Of Sales
-
1.41%
1.53%
1.47%
1.56%
1.65%
1.76%
1.52%
1.35%
1.42%
1.93%
Employee Cost
-
2,131.35
1,962.71
1,621.03
1,505.49
1,362.46
1,191.64
1,003.85
861.08
645.87
531.56
% Of Sales
-
18.37%
18.46%
18.29%
18.04%
18.52%
18.64%
17.65%
17.48%
17.25%
17.00%
Manufacturing Exp.
-
972.37
1,092.63
748.03
765.43
806.17
838.87
692.26
550.16
367.58
305.99
% Of Sales
-
8.38%
10.27%
8.44%
9.17%
10.96%
13.12%
12.17%
11.17%
9.82%
9.79%
General & Admin Exp.
-
819.84
641.25
506.77
525.62
512.52
469.90
379.78
334.28
238.92
184.73
% Of Sales
-
7.07%
6.03%
5.72%
6.30%
6.97%
7.35%
6.68%
6.79%
6.38%
5.91%
Selling & Distn. Exp.
-
1,339.88
1,070.10
700.98
854.48
726.21
675.43
596.44
503.69
434.56
367.31
% Of Sales
-
11.55%
10.06%
7.91%
10.24%
9.87%
10.57%
10.49%
10.23%
11.61%
11.75%
Miscellaneous Exp.
-
181.00
85.84
91.05
130.67
127.28
107.99
122.20
125.18
127.87
367.31
% Of Sales
-
1.56%
0.81%
1.03%
1.57%
1.73%
1.69%
2.15%
2.54%
3.42%
3.14%
EBITDA
2,196.76
1,609.45
2,052.92
1,942.39
1,473.39
1,114.77
1,008.92
998.95
853.25
421.83
409.95
EBITDA Margin
17.39%
13.88%
19.30%
21.91%
17.66%
15.15%
15.78%
17.56%
17.33%
11.27%
13.11%
Other Income
291.34
216.08
162.65
233.21
104.22
87.70
115.42
112.01
239.71
181.04
165.35
Interest
114.51
107.36
52.37
58.92
65.06
54.63
55.33
45.16
71.24
81.11
93.08
Depreciation
294.19
310.42
303.96
274.58
252.76
193.18
143.03
101.17
93.31
70.94
52.26
PBT
1,867.45
1,407.75
1,859.24
1,842.10
1,259.79
954.66
925.98
964.63
928.41
450.82
429.96
Tax
292.79
297.96
163.96
224.33
110.48
181.02
287.56
59.96
176.18
59.23
-5.36
Tax Rate
15.68%
22.84%
8.89%
12.18%
8.77%
18.96%
31.05%
6.22%
18.98%
13.14%
-1.25%
PAT
1,574.66
984.17
1,645.62
1,585.02
1,127.07
760.51
630.94
892.03
741.59
391.59
435.32
PAT before Minority Interest
1,573.19
1,006.81
1,680.32
1,617.77
1,149.31
773.64
638.42
904.67
752.23
391.59
435.32
Minority Interest
-1.47
-22.64
-34.70
-32.75
-22.24
-13.13
-7.48
-12.64
-10.64
0.00
0.00
PAT Margin
12.46%
8.48%
15.47%
17.88%
13.51%
10.34%
9.87%
15.68%
15.06%
10.46%
13.93%
PAT Growth
50.35%
-40.19%
3.82%
40.63%
48.20%
20.54%
-29.27%
20.29%
89.38%
-10.05%
 
EPS
131.66
82.29
137.59
132.53
94.24
63.59
52.75
74.58
62.01
32.74
36.40

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
9,045.29
8,637.90
7,376.73
6,160.67
5,439.34
4,863.77
4,467.64
3,691.96
2,999.05
2,584.97
Share Capital
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
11.96
Total Reserves
9,020.78
8,613.39
7,351.70
6,135.40
5,413.93
4,838.87
4,443.34
3,668.03
2,975.14
2,573.01
Non-Current Liabilities
-688.00
-892.74
-750.71
-540.58
-288.92
-358.61
-400.78
-306.15
200.60
323.92
Secured Loans
0.00
0.03
18.47
63.60
219.80
122.12
175.01
112.49
33.43
232.25
Unsecured Loans
0.00
9.35
9.46
10.31
11.50
8.61
6.55
10.97
0.00
0.00
Long Term Provisions
369.36
332.75
250.73
222.98
173.72
150.27
102.17
82.96
66.58
42.29
Current Liabilities
3,707.14
4,805.34
3,604.05
3,244.58
2,217.53
2,383.31
1,689.69
1,537.60
2,005.98
1,402.58
Trade Payables
1,165.03
1,173.38
1,069.41
954.05
962.25
960.71
741.37
580.48
465.93
305.73
Other Current Liabilities
838.80
771.42
643.11
555.47
428.08
520.04
339.25
366.01
327.06
201.28
Short Term Borrowings
1,307.12
2,570.62
1,635.96
1,503.51
671.27
761.27
472.37
464.17
1,128.57
845.22
Short Term Provisions
396.19
289.92
255.57
231.55
155.93
141.29
136.70
126.94
84.42
50.35
Total Liabilities
12,454.14
12,759.93
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43
5,291.28
4,311.47
Net Block
2,682.83
2,901.73
2,792.98
2,908.01
2,530.44
2,283.59
1,797.04
1,449.54
1,374.34
1,170.01
Gross Block
4,050.23
4,185.64
3,768.89
3,606.95
3,026.08
2,603.78
1,977.20
1,538.64
1,744.89
1,170.01
Accumulated Depreciation
1,367.40
1,283.91
975.91
698.94
495.64
320.19
180.16
89.10
370.55
0.00
Non Current Assets
3,724.45
4,324.50
3,482.53
3,507.32
3,284.43
2,996.80
2,954.64
2,249.73
2,953.23
2,709.33
Capital Work in Progress
323.24
339.48
393.28
362.97
492.96
380.97
299.26
172.42
110.69
0.00
Non Current Investment
304.61
231.67
153.95
91.50
95.74
98.45
259.44
234.39
419.73
338.24
Long Term Loans & Adv.
139.07
154.44
93.77
98.16
118.64
141.37
193.07
142.35
542.17
418.40
Other Non Current Assets
274.70
697.18
48.55
46.68
46.65
92.42
405.83
251.03
506.30
782.68
Current Assets
8,606.43
8,433.70
6,928.82
5,505.65
4,216.13
4,013.22
2,917.14
2,768.70
2,338.05
1,602.14
Current Investments
317.21
139.31
178.83
169.89
227.88
345.82
293.56
274.18
61.05
249.77
Inventories
2,607.53
3,005.53
2,312.44
1,818.82
1,499.87
1,442.19
1,206.00
909.37
784.23
620.33
Sundry Debtors
2,132.19
1,884.60
1,607.21
1,649.36
1,248.41
1,080.50
713.64
567.51
527.08
366.93
Cash & Bank
2,616.89
2,578.58
1,990.45
1,092.21
661.60
576.78
399.26
780.90
790.76
206.29
Other Current Assets
932.61
239.80
335.19
293.13
578.37
567.93
304.68
236.74
174.93
158.82
Short Term Loans & Adv.
687.93
585.88
504.70
482.24
405.00
390.63
171.35
141.30
114.85
110.04
Net Current Assets
4,899.29
3,628.36
3,324.77
2,261.07
1,998.60
1,629.91
1,227.45
1,231.10
332.07
199.56
Total Assets
12,330.88
12,758.20
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43
5,291.28
4,311.47

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
1,682.50
1,111.02
1,264.90
585.08
779.65
266.04
471.14
725.83
325.47
290.01
PBT
1,304.77
1,844.28
1,842.10
1,259.79
954.66
925.98
964.63
928.41
450.82
429.96
Adjustment
324.35
208.60
164.64
255.87
216.37
116.47
33.02
-14.42
-7.82
7.48
Changes in Working Capital
326.77
-544.96
-341.16
-647.20
-140.27
-573.24
-262.55
10.05
-11.89
-36.37
Cash after chg. in Working capital
1,955.89
1,507.92
1,665.58
868.46
1,030.76
469.21
735.10
924.04
431.11
401.07
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-273.39
-396.90
-400.68
-283.38
-251.11
-203.17
-263.96
-198.21
-105.64
-111.06
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
112.84
-1,435.13
-998.54
-741.35
-316.39
-357.23
-285.93
202.27
-236.97
350.44
Net Fixed Assets
-101.59
-254.26
-139.76
-310.63
-342.15
-531.27
-390.07
160.79
-111.90
-103.11
Net Investments
-476.94
-376.23
-196.34
-260.44
-151.10
-26.86
-359.97
-87.11
-129.77
-361.40
Others
691.37
-804.64
-662.44
-170.28
176.86
200.90
464.11
128.59
4.70
814.95
Cash from Financing Activity
-1,760.82
379.57
-271.75
79.15
-378.94
84.56
-137.88
-927.27
-51.78
-599.94
Net Cash Inflow / Outflow
34.52
55.46
-5.39
-77.12
84.32
-6.63
47.33
0.83
36.72
40.51
Opening Cash & Equivalents
232.18
174.22
175.94
249.05
166.71
166.63
127.03
123.75
100.82
57.31
Closing Cash & Equivalent
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.05
139.60
100.82

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
756.56
722.48
616.95
515.21
454.86
406.76
373.67
308.82
250.86
216.13
ROA
7.99%
14.50%
16.66%
13.92%
10.66%
9.91%
16.61%
14.59%
8.16%
10.14%
ROE
11.39%
20.99%
23.91%
19.82%
15.02%
13.69%
22.18%
22.47%
14.03%
18.28%
ROCE
13.09%
18.69%
22.56%
18.71%
16.49%
17.86%
21.31%
23.09%
13.27%
14.06%
Fixed Asset Turnover
4.36
3.84
3.56
3.74
3.80
3.75
3.33
3.07
2.65
2.89
Receivable days
40.86
41.72
45.33
42.66
39.69
38.15
39.95
39.57
42.27
38.62
Inventory Days
57.10
63.54
57.51
48.86
50.14
56.31
65.96
61.23
66.41
66.19
Payable days
97.40
114.79
118.18
52.05
60.17
61.04
52.36
49.96
45.83
42.61
Cash Conversion Cycle
0.57
-9.53
-15.34
39.47
29.66
33.42
53.55
50.84
62.85
62.19
Total Debt/Equity
0.14
0.30
0.23
0.26
0.17
0.21
0.15
0.18
0.44
0.44
Interest Cover
13.15
36.22
32.26
20.36
18.48
17.74
22.36
14.03
6.56
5.62

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Alkem Laboratories incorporates wholly owned subsidiary
    28th Mar 2024, 15:55 PM

    Alkem Medtech has been incorporated for exploring the medical device segment mainly in the cardiovascular and orthopedic fields

    Read More
  • USFDA concludes inspection at Alkem Laboratories’ manufacturing facility at Baddi
    28th Mar 2024, 11:42 AM

    At the end of the inspection, the company has received Form 483 with 10 observations

    Read More
  • USFDA issues EIR for Alkem Laboratories’ API manufacturing facility at Mandva
    28th Feb 2024, 15:47 PM

    The inspection has been classified as Voluntary Action Indicated and was closed accordingly

    Read More
  • Alkem Laboratories - Quarterly Results
    9th Feb 2024, 13:17 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.